Mouse models and genetic modifiers in X-linked adrenoleukodystrophy

Advances in Experimental Medicine and Biology

Volumn 544, Issue , 2003, Pages 75-93

  Heinzer, Ann K ^a   Mcguinness, Martina C ^a   Lu, Jyh Feng ^b   Stine, O Colin ^c   Wei, Heming ^a   Van Der Vlies, Mark ^a   Dong, Gaoxiang ^a   Powers, James ^d   Watkins, Paul A ^a   Smith, Kirby D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ABCD1 PROTEIN; ACYL COENZYME A DEHYDROGENASE; CD1D1 PROTEIN; CD1D2 PROTEIN; PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ADRENAL INSUFFICIENCY; ADRENOLEUKODYSTROPHY; CLINICAL FEATURE; CONFERENCE PAPER; DEMYELINATION; DISEASE CLASSIFICATION; DRUG EFFECT; GENE FUNCTION; HUMAN; INCIDENCE; INFERTILITY; MITOCHONDRION; MORTALITY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SPINAL CORD DISEASE; WHITE MATTER; X CHROMOSOME LINKED DISORDER;

EID: 12144289551     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9072-3_12     Document Type: Conference Paper

References (41)

1. Baes M., Gressens P., Baumgart E., Carmeliet P., Casteels M., Fransen M., Evrard P., Fahimi D., Declercq P.E., Collen D., van Veldhoven P.P., Mannaerts G.P., 1997, A mouse model for Zellweger syndrome. Nat Genet 17: 49-57.
2. Baumgart E., Vanhorebeek I., Grabenbauer M., Borgers M., Declercq P.E., Fahimi H.D., Baes M., 2001, Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse). Am J Pathol 159: 1477-1494.
3. Bezman L., Moser H.W., 1998, Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 76: 415-419.
4. Dean M., Allikmets R., 2001, Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33: 475-479.
5. Forss-Petter S., Werner H., Berger J., Lassmann H., Molzer B., Schwab M.H., Bernheimer H., Zimmermann F., Nave K.A., 1997, Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res 50: 829-843.
6. Goldfischer S., Moore C.L., Johnson A.B., Spiro A.J., Valsamis M.P., Wisniewski H.K., Ritch R.H., Norton W.T., Rapin I., Gartner L.M., 1973, Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 182: 62-64.
7. Hashmi M., Stanley W., Singh I., 1986, Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Lett 196: 247-250.
8. Heinzer A.K., Kemp S., Lu J.F., Watkins P.A., Smith K.D., 2002, Mouse very long-chain acyl-CoA synthetase in X-linked adrenoleukodystrophy. J Biol Chem 277: 28765-28773.
9. Heinzer A.K., Watkins P.A., Lu J.F., Kemp S., Moser A., Li Y.Y., Mihalik S.J., Powers J., Smith K.D., 2003, A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Hum Mol Genet in press.
10. Hoefler G., Hoefler S., Watkins P.A., Chen W.W., Moser A., Baldwin V., McGillivary B., Charrow J., Friedman J.M., Rutledge L., 1988, Biochemical abnormalities in rhizomelic chondrodysplasia punctata. J Pediatr 112: 726-733.
11. Ito M., Blumberg B.M., Mock D.J., Goodman A.D., Moser A.B., Moser H.W., Smith K.D., Powers J.M., 2001, Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 60: 1004-1019.
12. Jakobs B.S. and Wanders R.J., 1996, Impaired peroxisomal fatty acid oxidation in human skin fibroblasts with a mitochondrial acylcarnitine/ carnitine translocase deficiency. J Inherit Metab Dis 19: 185-187.
13. Kemp S., Pujol A., Waterham H.R., van Geel B.M., Boehm C.D., Raymond G.V., Cutting G.R., Wanders R.J., Moser H.W., 2001, ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 18: 499-515.
14. Kemp S., Wei H.M., Lu J.F., Braiterman L.T., McGuinness M.C., Moser A.B., Watkins P.A., Smith K.D., 1998, Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 4: 1261-1268.
15. Kobayashi T., Shinnoh N., Kondo A., Yamada T., 1997, Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun 232: 631-636.
16. Kok F., Neumann S., Sarde C.O., Zheng S., Wu K.H., Wei H.M., Bergin J., Watkins P.A., Gould S, Sack G., 1995, Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum Mutat 6: 104-115.
17. Lu J.F., Lawler A.M., Watkins P.A., Powers J.M., Moser A.B., Moser H.W., Smith K.D., 1997, A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A 94: 9366-9371.
18. Maestri N.E. and Beaty T.H., 1992, Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. Am J Med Genet 44: 576-582.
19. McGuinness M.C., Lu J.F., Zhang H.P., Dong G.X., Heinzer A.K., Watkins P.A., Powers J., Smith K.D., 2003, Role of ALDP (ABCD1) and Mitochondria in X-Linked Adrenoleukodystrophy. Mol Cell Biol 23: 744-753.
20. McGuinness M.C., Zhang H.P., Smith K.D., 2001, Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol Genet Metab 74: 256-263.
21. Moser A.B., Kreiter N., Bezman L., Lu S., Raymond G.V., Naidu S., Moser H.W., 1999, Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 45: 100-110.
22. Moser H.W., Moser A.B., Smith K.D., Bergin A., Borel J., Shankroff J., Stine O.C., Merette C., Ott J., Krivit W., 1992, Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 15: 645-664.
23. Moser H.W., Smith, K.D., Watkins, P.A., Powers, J.M., Moser, A.B., 2000, X-Linked Adrenoleukodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease, vol. III, 8th Edition (C.R. Scriver, W.S. Sly, B. Childs, A.L. Beaudet, D. Valle, K.W. Kinzler and B. Vogelstein, eds.) McGraw Hill; New York, pp 3257-3301.
24. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JL, Aubourg P. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361: 726-730.
25. Powers J.M., DeCiero D.P., Cox C., Richfield E.K., Ito M., Moser A.B., Moser H.W., 2001, The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 60: 493-501.
26. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW., 2000, Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 59: 89-102.
27. Powers J.M., Schaumburg H.H., Johnson A.B., Raine C.S., 1980, A correlative study of the adrenal cortex in adreno-leukodystrophy - evidence for a fatal intoxication with very long chain saturated fatty acids. Invest Cell Pathol 3: 353-376.
28. Pujol A., Hindelang C., Callizot N., Bartsch U., Schachner M., Mandel J.L., 2002, Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 11: 499-505.
29. Rizzo WB, Avigan J, Chemke J, Schulman JD. Adrenoleukodystrophy: very long-chain fatty acid metabolism in fibroblasts. Neurology 1984; 34: 163-169.
30. Schaumburg H.H., Powers J.M., Raine C.S., Spencer P.S., Griffin J.W., Prineas J.W., Boehme D.M., 1977, Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic, and biochemical aspects. Neurology 27: 1114-1119.
31. Sereni C., Paturneau-Jouas M., Aubourg P., Baumann N., Feingold J., 1993, Adrenoleukodystrophy in France: an epidemiological study. Neuroepidemiology 12: 229-233.
32. Sheffield V.C., Carmi R., Kwitek-Black A., Rokhlina T., Nishimura D., Duyk G.M., Elbedour K., Sunden S.L., Stone E.M., 1994, Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping. Hum Mol Genet 3: 1331-1335.
33. Singh I., Moser A.E., Moser H.W., Kishimoto Y., 1984, Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res 18: 286-290.
34. Smith K.D., Kemp S., Braiterman L.T., Lu J.F., Wei H.M., Geraghty M., Stetten G., Bergin J.S., Pevsner J., Watkins P.A., 1999, X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 24: 521-535.
35. Smith K.D., Sack, G., Beaty, T., Bergin, A., Naidu, S., Moser, H. W., 1991, A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am J Hum Genet 49: 576.
36. Steinberg S.J., Kemp S., Braiterman L.T., Watkins P.A., 1999, Role of very-long-chain acylcoenzyme A synthetase in X-linked adrenoleukodystrophy. Ann Neurol 46: 409-412.
37. Uchida Y., Kondo N., Orii T., Hashimoto T., 1996, Purification and properties of rat liver peroxisomal very-long-chain acyl-CoA synthetase. J Biochem (Tokyo) 119: 565-571.
38. van Geel B.M., Assies J., Haverkort E.B., Koelman J.H., Verbeeten B. Jr., Wanders R.J., Barth P.G., 1999, Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J Neurol Neurosurg Psychiatry 67: 290-299.
39. van Geel B.M., Assies J., Weverling G.J., Barth P.G., 1994, Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindreds. Neurology 44: 2343-2346.
40. Wanders R.J. and Tager J.M., 1991, Peroxisomal fatty acid beta-oxidation in relation to adrenoleukodystrophy. Dev Neurosci 13: 262-266.
41. Wei H., Kemp S., McGuinness M.C., Moser A.B., Smith K.D., 2000, Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol 47: 286-296.